Global Mucosal Atomization Devices Market Size (2024 - 2029)

Mucosal Atomization Devices Market Analysis

The mucosal atomization devices market is projected to record a CAGR of nearly 7.25% over the forecast period.

During the initial phase, the COVID-19 pandemic adversely affected communities, industries, and markets, including mucosal atomization devices. For instance, as per a survey conducted by the International Archives of Allergy and Immunology in January 2021, only 13% of physicians continued skin prick testing with commercial inhalant extracts, while 31% of physicians performed skin pricking tests in rare cases. However, all the respondents were observed to be continuing their asthma and allergic rhinitis medication, including inhaled corticosteroids, long-acting β2-agonists, Montelukast sodium, antihistamines, and nasal steroids. Over 92% of physicians reported prescribing inhaled medication to COVID-19 patients for instances of emergency management. In the current scenario, as the restrictions eased, the market is anticipated to witness growth because of the increase in the adoption of mucosal atomization devices due to the advantages offered by the devices in drug delivery. For instance, as per the article published in February 2022 in eBioMedicine journal, immune responses at the mucosal and systemic levels may be induced via mucosal immunization. Nine vaccines against different mucosal infections have been licensed for human use, including eight provided orally and one given intranasally (IN), all of which are complete viral vaccines.

The major factor contributing to the market growth is the increase in the prevalence of allergic rhinitis, sinus, and other target diseases across the world. For instance, as per the Allergy Capital Report 2022, one of the most common allergic conditions is seasonal allergic rhinitis, often called 'hay fever.' About 7.7% of adults and 7.2% of children have been diagnosed with seasonal allergic rhinitis in the United States. Similarly, as per the June 2022 update from European Parliament, allergies are among the most common chronic noncommunicable diseases in Europe. In 2022, about 150 million people in Europe live with an allergic condition, such as allergic rhinitis, asthma, atopic eczema, or a food allergy. Hence, the rise in allergy diseases across the globe is anticipated to increase the demand for mucosal atomization devices, thereby driving market growth.

Mucosal atomization devices help in faster delivery of medication in the bloodstream, thus reducing the time for therapeutics to act on the concerned medical issue. As these drugs directly enter the bloodstream, they avoid first-pass metabolism and offer quicker results. Further, the increasing number of epilepsy cases among the population is increasing the adoption of mucosal atomization devices to quickly administer the drug intranasally in emergencies. For instance, according to an article published in Taylor and Francis, in March 2021, it had been observed that midazolam mucosal nasal spray rapidly absorbs, in adult and pediatric patients with seizures/epilepsy, and helps in terminating the seizure activity. This shows the viable tolerability of midazolam nasal spray through mucosal atomization devices in the patients which is expected to increase the demand for midazolam nasal spray for treating patients with epilepsy, thereby propelling the market growth.

Moreover, technological advancements and developments in mucosal atomization devices are expected to boost market growth since they increase convenience and thereby lead to the adoption of the devices. For instance, in October 2021, Alcove Manufacturing and Distribution Inc. and Pulmodyne Inc. collaborated to expand distribution, consolidate manufacturing, and continue cooperative research of novel atomization technologies. With this new partnership, Pulmodyne distributed the EZ-Spray Atomization System through its existing channels. In addition to distribution, the partnership seeks to innovate further in the space, and this relationship will allow the two experienced companies to optimize product designs quickly.

In the midst of these developments, side effects due to the overdose of drugs are expected to restrain the market growth.

Mucosal Atomization Devices Industry Segmentation

As per the scope of the report, mucosal atomization devices are specific types of devices used to administer drugs through the tracheal mucosal, oral, and nasal surfaces. They are systematic and enable needle-free drug delivery. They are largely used during emergency and pre-hospital treatments. 

The Mucosal Atomization Devices Market is Segmented by Product Type (Gas-propelled and Electrical), End User (Hospital, Clinics, and Other End Users), and Geography (North America, Europe, Asia-Pacific, and the Rest of the World). The report offers the value (in USD million) for the above segments.